Mylan’s attempts to quiet a public anger over its $600 price tag for EpiPen weren’t enough to escape a congressional inquiry.

The House Oversight and Government Reform Committee called for the generic drug maker to turn over documents on the company’s revenue and manufacturing costs to better understand the price increase for the life-saving allergy treatment.